Cyprus/Greece/MaltaCyprusGreeceMalta

New biotech laws for Malta

12.08.2005

La Valetta - After a broad discussion process Malta's Social Affairs Committee has presented a draft regulation on biotechnology and assisted reproduction to the parliament in July.
According to the proposals the fertilised ovum will be given the status of an embryo with full human rights. Consequently, creation of embryos for research purposes and cloning will be prohibited. But cells extracted from the umbilical cord blood, placenta, as well as adult stem cells could be used for research, while cells from a natural miscarriage are accessible only with the permission of the parents.
Genetic diagnosis should be allowed on condition that it is used for medical and forensic reasons only, or to correct specific abnormalities in the embryo. Pre-implantation diagnosis will be prohibited, pre-natal testing should be allowed if there is a possibility of the parents passing on a genetic disease to their children.
Assisted procreation should be allowed under certain conditions: third party donors and surrogate motherhood should not be allowed. In cases where the parents are not able to use the embryos - due to the mother's death, for example - these embryos can be put up for adoption according to Maltese law.
Nationalist MP Clyde Puli - Chairman of the Committee - pointed out that after seven months of discussion, the time has come to take a decision. Concerning the protest of members of opposition he added that once the law was implemented, changes could be made through a legal notice.
However, the Committee's recomendations have been met with mixed reactions in professional circles. While many medical professionals agree that it is important to include a clear legal definition of the beginning of human life, most doctors seem to see the definition put forward by the Committee as, at best, “a conservative compromise.” Especially gynaecologists have expressed their concern that the Committee's definition might “hinder the process of IVF”.

Cyprus/Greece/MaltaCyprusGreeceMalta

19.03.2008

Athens – Greek conglomerate Alapis is further expanding its healthcare arm (production of veterinary pharmaceuticals, medical equipment and nutritional supplements), an area that made up 75% of its total EBITDA of €117.3m in...

Cyprus/Greece/MaltaCyprusGreeceMalta

24.09.2007

Athens – Greek chemical and human and veterinary pharmaceutical company Alapis S.A., which was formed in May by a merger of the Greek firms Veterin, Ebik and Elpharma, is expanding rapidly through acquisitions in south-eastern...

Cyprus/Greece/MaltaCyprusGreeceMalta

11.07.2007

Athens – At the end of May, Greece has launched its official site for the Greek National Contact Point (NCP) for the FP7’s thematic areas “Health“ and “Food, Agriculture and Fisheries, and Biotechnology“ (www.ncp-bionova.gr/)....

Cyprus/Greece/MaltaCyprusGreeceMalta

16.05.2007

Athens – Greek Deputy Agriculture Minister Alexandros Kontos has renewed a decree banning the sale of genetically engineered Mon810 Bt maize varieties for another 18 months after an ultimatum of the European Commission ran out in...

Cyprus/Greece/MaltaCyprusGreeceMalta

16.03.2007

Ioannina – Tumor markers are specific to a certain type of cancer and its developmental stage. They are used to estimate a prognosis for the development and treatment of the cancer. Researchers led by John Ioannidis from the...

Politics / Law, Cyprus/Greece/MaltaCyprusGreeceMalta

21.11.2006

Athens – The Greek government and the European Investment Fund (EIF) signed a Memorandum of Understanding in October, which is to implement ‘Jeremie’. The initiative allows the EU Member States and regions to use part of their...

Cyprus/Greece/MaltaCyprusGreeceMalta

12.05.2006

Athens/Napa - Senetek PLC, a US-biopharmaceutical company focused on developing and co-marketing products in the key categories skincare and dermatological worldwide, announced in March that they have signed a cooperative...

Cyprus/Greece/MaltaCyprusGreeceMalta

17.03.2006

Athens/Paris - US-based drug development company Immuno-Designed Molecules (IDM) Inc. signed in February an exclusive licensing and marketing agreement for its cancer drug Junovan (Muramyl Tripeptide Phosphatidylethanolamine) in...

Cyprus/Greece/MaltaCyprusGreeceMalta

17.03.2006

Athens/Brussels - The European Commission has decided that the Greek national ban of MON810 maize is not properly justified and has therefore ordered to lift the ban. Up to now, Greece had referred to the safeguard clause for...

Cyprus/Greece/MaltaCyprusGreeceMalta

29.01.2006

Athens/Nikosia - Drug developer Samaritan Europe has entered into an exclusive distribution agreement with Three Rivers Pharmaceuticals for the marketing and sales of Amphocil® (amphotericin B cholesteryl sulfate complex for...

Displaying results 11 to 20 out of 47

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-cyprus-greece-malta/browse/1/article/new-biotech-laws-for-malta.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA74.95 CHF10.30%
  • BIOTEST80.50 EUR6.83%
  • WILEX2.22 EUR5.71%

FLOP

  • 4SC1.20 EUR-6.25%
  • VITA 343.78 EUR-2.83%
  • EPIGENOMICS3.12 EUR-2.50%

TOP

  • MAGFORCE6.50 EUR20.4%
  • LONZA101.10 CHF9.2%
  • SANTHERA74.95 CHF7.8%

FLOP

  • WILEX2.22 EUR-32.3%
  • VITA 343.78 EUR-20.1%
  • MOLOGEN7.80 EUR-17.5%

TOP

  • SANTHERA74.95 CHF3556.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.40 EUR185.7%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014


Current issue

All issues

Product of the week

Products